Sun Pharmaceutical settlement with end payers in US generic drug suit gets preliminary nod
MLex Summary: Sun Pharmaceutical’s $200 million settlement to resolve US antitrust claims from end purchasers accusing it of fixing the prices of generic pharmaceuticals has been granted preliminary approval by a...To view the full article, register now.
Already a subscriber? Click here to view full article